Each biological or cybernetic enhancement agent binds to a target pathway with a saturating, sigmoidal dose–response relationship described by the Hill equation. Effect rises steeply near the potency constant (EC50) and plateaus at a modality-specific maximum (Emax), reflecting the biological ceiling of any single intervention.
E(D) = Emax · D^n / (EC50^n + D^n)
R(D) = 100 / (1 + e^-((D - 70) / 12)) · riskMult
Net(D) = E(D) - R(D)
Risk follows a separate logistic curve that only becomes steep at high doses — capturing how enhancement side effects (off-target mutation, immune rejection, hardware failure, toxicity) are often negligible at low intervention levels but escalate sharply near the upper safe limit. Each modality carries its own maximum effect and risk multiplier.
- Modality buttons — switch between genetic (high potency, elevated mutation risk), cybernetic (capped effect, lower biological risk), and pharmacological (moderate effect and risk) enhancement.
- Enhancement Dose — the intervention intensity D fed into both curves.
- Potency (EC50) — the dose producing half-maximal effect; lower EC50 means the agent is more potent.
- Hill Coefficient n — controls curve steepness / cooperativity of binding.
- Play/Pause — freezes cell-field animation to inspect a snapshot state; Reset returns all controls to defaults.
This same dose–response / risk-escalation framework underlies real pharmacology (therapeutic index), gene-therapy vector dosing, and neural-implant calibration — the central ethical question in enhancement research is where to draw the line between the plateauing benefit curve and the accelerating risk curve.